<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02586129</url>
  </required_header>
  <id_info>
    <org_study_id>YH14755-301</org_study_id>
    <nct_id>NCT02586129</nct_id>
  </id_info>
  <brief_title>Clinical Trial of YH14755 in Subjects With Dyslipidemia and Type II Diabetes</brief_title>
  <official_title>Randomized, Double-blind, Active-controlled, Multicenter Phase 3 Trial to Evaluate the Safety and Efficacy of YH14755 in Subjects With Dyslipidemia and Type II Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yuhan Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yuhan Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized, double-blind, active-controlled, multicenter phase 3 trial to evaluate the safety
      and efficacy of YH14755 in subjects with dyslipidemia and Type II Diabetes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase 3 trial to evaluate the safety and efficacy of YH14755 in subjects with
      dyslipidemia and Type II Diabetes.

      In YH14755 treatment group, 88 subjects will be assigned and the subjects administer YH14755
      for 16 weeks.

      In Metformin treatment group, 88 subjects will be assigned and the subjects administer
      Metformin for 16 weeks.

      In Rosuvastatin treatment group, 88 subjects will be assigned and the subjects administer
      Rosuvastatin for 16 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Actual">July 7, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in LDL Cholesterol</measure>
    <time_frame>Change from baseline at 16 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in HbA1c</measure>
    <time_frame>Change from baseline at 16 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">264</enrollment>
  <condition>Dyslipidemia</condition>
  <condition>Type II Diabetes</condition>
  <arm_group>
    <arm_group_label>YH14755</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PO, Once Daily, 16 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PO, Once Daily, 16 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rosuvastatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PO, Once Daily, 16 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YH14755</intervention_name>
    <description>20/1500mg, QD</description>
    <arm_group_label>YH14755</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>1500mg, QD</description>
    <arm_group_label>Metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin</intervention_name>
    <description>20mg, QD</description>
    <arm_group_label>Rosuvastatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed Informed Consent

          -  Subjects with Dyslipidemia and Type II Diabetes

          -  6.5% ≤ HbA1c level ≤ 9.0% and LDL-C level ≤ 250mg/dL(6.5 nmal/L) at screening

          -  BMI ≤ 45kg/m2

          -  Subjects who dose not administered diabetes treatment at least 4 weeks prior to
             screening visit.

          -  19 years later, men and women under the age of 75

        Exclusion Criteria:

          -  Pregnant women, nursing mothers or subject who does not agree to assigned
             contraception in the study

          -  Subject with type I Diabetes

          -  Subject with hypertension which does not controlled by treatment(have blood pressure &gt;
             160/110mmHg)

          -  Have a known allergy to drugs

          -  Have administered Cyclosporine

          -  Have administered Obesity treatment within 12 weeks prior to screening visit

          -  Participated in any other clinical trials within 30 days prior to the first
             administration

          -  Subject who is judged to be ineligible by investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hakcheol Jang, M.D., Ph.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Internal Medicine, SNU Bundang Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National Universitiy Bundang Hospital</name>
      <address>
        <city>Seongnam-Si</city>
        <state>Gyeonggi-Do</state>
        <zip>463-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 22, 2015</study_first_submitted>
  <study_first_submitted_qc>October 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 26, 2015</study_first_posted>
  <last_update_submitted>August 22, 2017</last_update_submitted>
  <last_update_submitted_qc>August 22, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Dyslipidemias</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

